With the upload of data from more than 100 clinical trials comprising almost 60.000 individuals completed, Hypo-RESOLVE has taken a great step towards the creation of a secure, sustainable database. P...
The Hypo-RESOLVE consortium is very pleased to announce that the EC accepted its 2nd progress report covering the achievements of the second year in Hypo-RESOLVE. During those twelve months, considera...
The Hypo-RESOLVE Consortium is pleased to communicate that on 24th September 2020 the IMI published The constant threat of 'hypos' takes a heavy toll on people with diabetes based on a Q&A interview...
On 21st September 2020, the Hypo-RESOLVE Managing Board met virtually to present work progress, discuss future steps and also evaluate the impact the COVID-19 pandemic is having on the project’s progr...
Originally scheduled to take place in Wiesbaden, Germany, from 13-14 May 2020, the Hypo-RESOLVE Annual Progress Meeting 2020 had to be reorganised as a web meeting in face of the COVID-19 pandemic. Ow...
On 4th February 2020, the Managing Board of Hypo-RESOLVE met for its fifth face-to-face meeting at Frankfurt Airport. Besides presenting updates on their progress and first results from different Work...
Paper on our work accepted by Diabetic Medicine
An extremely successful Hypo-RESOLVE work package 2 (WP2) face-to-face meeting was held in Copenhagen on January 17 with representatives from almost all partners participating. The full day meeting st...
The Hypo-RESOLVE consortium is very pleased to announce that the EC accepted its 1st progress report covering the achievements of a very exciting first year. During the initial twelve months of the pr...